New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

1

AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of Advanced Parkinson’s Disease

AbbVie submitted a New Drug Application to the U.S. Food and Drug Administration for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in patients with advanced Parkinson’s disease.

2

N. Korea reports over 200,000 fever cases for 5th day amid COVID wave – Yonhap

North Korea reported more than 200,000 new patients suffering from fever for a fifth consecutive day as the country fights its first confirmed coronavirus outbreak, South Korea’s Yonhap news agency said on May 21, citing the North’s state broadcaster.

3

U.S. CDC says adenovirus leading hypothesis for severe hepatitis in children

Infection with adenovirus, a common childhood virus, is the leading hypothesis for recent cases of severe hepatitis of unknown origin in children that have led to at least six deaths, U.S. health officials said on May 20.

4

FDA approves Dupixent as first treatment for adults and children aged 12 and older with eosinophilic esophagitis

The U.S. Food and Drug Administration approved Sanofi’s Dupixent (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis (EoE) aged 12 years and older, weighing at least 40 kg. With this approval, Dupixent is the first and only medicine specifically indicated to treat EoE in the United States.

8

Researchers develop CRISPR mechanism to edit multiple DNA sites at once

Rice University researchers in Houston used the foundation of CRISPR/Cas9 technology to develop “drive-and-process” arrays, or DAP for short. The name may be simple, but the technology is complex and could be as groundbreaking as its predecessor. DAP is a mechanism that enables the editing of multiple DNA sites – rather than one at a time – to comprehensively reverse polygenic diseases resulting from multiple genetic predispositions.

9

Following patient death, FDA puts Foghorn study on partial hold

The U.S. Food and Drug Administration issued a partial clinical hold for Foghorn Therapeutics’ Phase I clinical study, investigating the safety and efficacy of FHD-286 in patients with relapsed and/or refractory acute myelodysplastic leukemia (AML) and myelodysplastic syndromes (MDS). The hold follows a serious adverse event in which a study participant died after developing possible differentiation syndrome.